Role of the Gonadotrophin-Releasing Hormone Antagonists and Advanced Hormone-Dependent Prostate Cancer - Journal review
September 9, 2016
Authors: Derek J. Rosario, Patrick Davey, James Green, Damien Greene, Bruce Turner, Heather Payne and Mike Kirby
An overview of the discussion includes:
-Comparing gonadotrophin-releasing (GnRH) hormone antagonists and agonists as ADT therapy for advanced prostate cancer
-GnRH antagonists and the rapid suppression of luteinizing hormone, follicle-stimulating hormone and testosterone.
-Scientific evidence and improved disease control with GnRH antagonists.
-Cardiac events among men receiving GnRH antagonists than agonists.
-Considering risk factors when making treatment decisions
Read the Article Abstract
Thomas E. Keane, MBBCh, FRCSI, FACS, is Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers.
An avid researcher, Dr. Keane has served as principal investigator or coinvestigator on more than 20 major clinical and preclinical studies, funded by grants from the National Institutes of Health as well as industry-funded. Much of his work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate the efficacy of new therapies as they relate to GU malignancies with particular reference to cytotoxic agents, sphingolipids, and boron-containing compounds. He holds a U.S. patent for sphingolipid derivatives and their use